UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital?

Rheumatology (Oxford, England), 2018-04, Vol.57 (suppl_3)

2018

Volltextzugriff (PDF)

P50: Etanercept treatment ameliorates the core characteristic in the Letrozole induced PCOS model

American journal of reproductive immunology (1989), 2018-06, Vol.80 (S1), p.79-79

2018

Volltextzugriff (PDF)

ORGANISING PNEUMONIA SECONDARY TO ETANERCEPT

Respirology (Carlton, Vic.), 2017-11, Vol.22 (S3), p.255-255

2017

Volltextzugriff (PDF)

Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept

International journal of molecular sciences, 2018-09, Vol.19 (10), p.2938

2018

Volltextzugriff (PDF)

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

PloS one, 2017-04, Vol.12 (4), p.e0175207-e0175207

2017

Volltextzugriff (PDF)

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.51-57

2017

Volltextzugriff (PDF)

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938

2017

Volltextzugriff (PDF)

Tumour necrosis factor blockade after asphyxia in foetal sheep ameliorates cystic white matter injury

Brain (London, England : 1878), 2023-04, Vol.146 (4), p.1453-1466

2023

Volltextzugriff (PDF)

Etanercept Reduces Neuron Injury and Neuroinflammation via Inactivating c-Jun N-terminal Kinase and Nuclear Factor-κB Pathways in Alzheimer’s Disease: An In Vitro and In Vivo Investigation

Neuroscience, 2022-02, Vol.484, p.140-150

2022

Volltextzugriff (PDF)

TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models

Nature communications, 2022-02, Vol.13 (1), p.676-676, Article 676

2022

Volltextzugriff (PDF)

Transmembrane TNF-α: structure, function and interaction with anti-TNF agents

Rheumatology (Oxford, England), 2010-07, Vol.49 (7), p.1215-1228

2010

Volltextzugriff (PDF)

Lungentuberkulose unter Therapie mit Tocilizumab/Etanercept

Aktuelle Rheumatologie, 2023-10

2023

Volltextzugriff (PDF)

药物 Tildrakizumab 治疗斑块型银屑病的研究

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e208-e208

2020

Volltextzugriff (PDF)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects

British journal of clinical pharmacology, 2016-07, Vol.82 (1), p.64-73

2016

Volltextzugriff (PDF)

Therapeutic Potential of TNF-α Inhibition for Alzheimer's Disease Prevention

Journal of Alzheimer's disease, 2020-01, Vol.78 (2), p.619-626

2020

Volltextzugriff (PDF)

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288

2017

Volltextzugriff (PDF)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1112-1124

2019

Volltextzugriff (PDF)

A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.65-71

2017

Volltextzugriff (PDF)

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

Journal of the American Academy of Dermatology, 2016-02, Vol.74 (2), p.280-287.e3

2016

Volltextzugriff (PDF)

Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases

Clinical infectious diseases, 2015-08, Vol.61 (3), p.409-417

2015

Volltextzugriff (PDF)

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2020-01, Vol.72 (1), p.31-40

2020

Volltextzugriff (PDF)

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis

Journal of rheumatology, 2018-02, Vol.45 (2), p.195-201

2018

Volltextzugriff (PDF)

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes

British journal of clinical pharmacology, 2017-04, Vol.83 (4), p.732-741

2017

Volltextzugriff (PDF)

Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats

Pharmaceutical research, 2020-08, Vol.37 (8), p.155, Article 155

2020

Volltextzugriff (PDF)

1 – 25 von 9.316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(8.122)
Mit Volltextzugriff
(6.560)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Etanercept
(8.299)
Science & Technology
(6.434)
Life Sciences & Biomedicine
(6.273)
Humans
(6.244)
Female
(3.478)
Male
(3.455)
Infliximab
(3.140)
Receptors, Tumor Necrosis Factor - Therapeutic Use
(3.106)
Immunoglobulin G - Therapeutic Use
(3.103)
Rheumatology
(2.757)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(2.718)
Middle Aged
(2.664)
Adult
(2.361)
Rheumatoid Arthritis
(2.220)
Antirheumatic Agents - Therapeutic Use
(2.126)
Arthritis, Rheumatoid - Drug Therapy
(2.023)
Treatment Outcome
(2.018)
Adalimumab
(1.893)
Antibodies, Monoclonal - Therapeutic Use
(1.657)
Biological And Medical Sciences
(1.484)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(6.719)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(4.496)
EZB Electronic Journals Library
(3.825)
Ingenta
(3.606)
Single Journals
(1.639)
2022 ECC(Springer)
(1.481)
Wiley Online Library Journals
(1.354)
Elsevier ScienceDirect Journals Complete
(1.294)
Wiley Online Library Full Collection 2018
(1.154)
BMJ_英国医学会期刊
(1.084)
IngentaConnect Journals
(1.058)
BMJ Journals Archiv - DFG Nationallizenzen
(868)
Oxford University Press Full Collection 2022
(761)
Taylor & Francis Journals
(663)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(651)
Taylor & Francis Online
(627)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(594)
Taylor & Francis Online
(542)
Nexis Uni
(393)
Oxford Journals 2020 Medicine
(334)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of The Rheumatic Diseases
(984)
Journal Of Rheumatology
(298)
Rheumatology
(250)
British Journal Of Dermatology
(198)
Arthritis And Rheumatism
(197)
Clinical Rheumatology
(195)
Reactions Weekly
(163)
Journal Of The American Academy Of Dermatology
(155)
Clinical And Experimental Rheumatology
(145)
Modern Rheumatology
(145)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(71)

Menü

Weitere Dienste

Einstellungen

061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital?

P50: Etanercept treatment ameliorates the core characteristic in the Letrozole induced PCOS model

ORGANISING PNEUMONIA SECONDARY TO ETANERCEPT

Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Tumour necrosis factor blockade after asphyxia in foetal sheep ameliorates cystic white matter injury

Etanercept Reduces Neuron Injury and Neuroinflammation via Inactivating c-Jun N-terminal Kinase and Nuclear Factor-κB Pathways in Alzheimer’s Disease: An In Vitro and In Vivo Investigation

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models

Transmembrane TNF-α: structure, function and interaction with anti-TNF agents

Lungentuberkulose unter Therapie mit Tocilizumab/Etanercept

药物 Tildrakizumab 治疗斑块型银屑病的研究

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects

Therapeutic Potential of TNF-α Inhibition for Alzheimer's Disease Prevention

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes

Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats

Suchergebnisse filtern